ABSTRACT
On the basis of Section 140h of Social Code Book V (German abbreviation: SGB V), which had been newly included in 2004, the Federal Government Commissioner for Patients' Affairs speaks out in favor of a meticulous implementation of patients' right to education, information and joint decision-making in all spheres of the health care system, whenever the commissioner attends the respective panels or events, and also in public. Currently, the commissioner is member of a parliamentary working group which is charged with the elaboration of the contents of a law relating to patients' rights, and experts and patients' organizations are involved in this procedure as well. For this purpose, but also with regard to other key panels of the health care system, self-help organizations are important partners for collaboration, due to their commitment, their experiences and the inspirations they provide. Therefore, they have been strengthened in essential aspects by the policy of the Federal Government over the past few years.
Subject(s)
Advisory Committees/organization & administration , Delivery of Health Care/legislation & jurisprudence , Federal Government , Patient Participation/legislation & jurisprudence , Patient Rights/legislation & jurisprudence , Self Care , Germany , Humans , Organizational Objectives , Physician-Patient RelationsABSTRACT
A multicenter field efficacy study was performed in six farms located in Belgium, France and Germany with a history of suspected coccidiosis outbreaks and the proven presence of Eimeria bovis and/or Eimeria zuernii. At each of these trial sites the calves were randomly allocated to two groups (T, treated; C, control) of similar size. In total, 231 calves were included in the study. Group T calves (n=116) were drenched with a single dose of diclazuril (Vecoxan, 1mg/kg body weight) close to the time of expected outbreak of coccidiosis (day 1 of the study period), group C calves (n=115) served as placebo-treated controls. Although E. bovis and/or E. zuernii were identified at all trial sites, clinical coccidiosis was only noted in 16% of the group C calves. At day 5 of the study period (4 days after treatment), faecal oocyst counts (opg, oocysts per gram) were substantially lower in group T ("short-term effect") compared to group C. At four trial sites, the respective values of groups T and C were significantly different (P=0.0132 to P=0.0001) in favour of group T. For the pooled data of all trial sites, this effect was highly significant (P<0.0001). The overall faecal oocyst counts from day 3 until day 21 of the study period ("Area Under the Curve") was significantly reduced in group T by 87.2-99.5% ("long-term effect") at five trial sites (P=0.0139 to P<0.0001). The pooled data revealed a highly significant effect of treatment on oocyst excretion over the observation period (P<0.0001). On five of the six trial sites, the average weight gain was higher in group T than in group C. On those trial sites, the average weight gain of group T calves exceeded that of the controls by 95-268g/day and by 2.0-6.0kg over the study period. This effect was statistically significant (P<0.01) at one trial site. Altogether the calves of group T gained on average 129g more weight daily than the controls (+2.7kg over the study period). For these pooled data, statistical analysis confirmed the positive effect of treatment of calves exposed to coccidiosis on growth performance (P=0.003). In conclusion, metaphylactic treatment with diclazuril efficiently controls coccidiosis in calves thus reducing environmental contamination with oocysts and preventing negative effects of natural exposure to coccidiosis on growth performance of calves.
Subject(s)
Cattle Diseases/drug therapy , Cattle Diseases/parasitology , Cattle/growth & development , Coccidiosis/veterinary , Coccidiostats/therapeutic use , Eimeria/physiology , Nitriles/therapeutic use , Oocysts/drug effects , Triazines/therapeutic use , Animals , Coccidiosis/drug therapy , Coccidiosis/parasitology , Feces/parasitology , Female , Male , Oocysts/physiologyABSTRACT
The pharmacokinetics of escitalopram (S-citalopram) and its principal metabolite, S-demethylcitalopram (S-DCT), were investigated after intravenous and oral administration to healthy subjects. After intravenous infusion of escitalopram, the mean systemic clearance and volume of distribution were 31 L/h and 1,100 L, respectively. After oral administration of single or multiple doses, the absorption was relatively fast, with the maximum observed plasma or serum concentration (C(max)) attained after 3 to 4 hours. The mean half-lives were 27 and 33 hours, respectively; steady state was attained within 10 days. The area under the plasma or serum concentration time curve from time zero to 24 hours and C(max) was both linear and proportional to the dose. The apparent volume of distribution was around 20 L/kg. Comparison of the systemic and oral clearance implied a high absolute bioavailability. There was no evidence of interconversion from S-citalopram to R-citalopram either in plasma or in urine. Concurrent intake of food had no effect on the pharmacokinetics of escitalopram or its metabolite. All treatments were well tolerated.
Subject(s)
Antidepressive Agents, Second-Generation/pharmacokinetics , Citalopram/pharmacokinetics , Selective Serotonin Reuptake Inhibitors/pharmacokinetics , Administration, Oral , Adult , Antidepressive Agents, Second-Generation/administration & dosage , Antidepressive Agents, Second-Generation/adverse effects , Biological Availability , Citalopram/administration & dosage , Citalopram/adverse effects , Double-Blind Method , Drug Administration Schedule , Female , Food-Drug Interactions , Humans , Infusions, Intravenous , Male , Selective Serotonin Reuptake Inhibitors/administration & dosage , Selective Serotonin Reuptake Inhibitors/adverse effectsABSTRACT
The efficacy of metaphylactic treatment with toltrazuril (Baycox 5% suspension) against natural infections with Eimeria bovis and/or Eimeria zuernii in calves was investigated. The study was conducted with 208 calves on five calf-rearing farms in Germany and the Czech Republic. All participating farms had a notable incidence of coccidiosis. Animals were treated 14 days after stabling in the respective facility. One group was treated with 15 mg toltrazuril/kg body weight, and a second group served as the sham-treated control. Assessment of efficacy was based on faecal consistency and oocyst excretion of E. bovis and E. zuernii, both investigated throughout the study. Duration and rate of oocyst excretion as well as number of scour days with E. bovis or E. zuernii oocyst shedding and the severity of diarrhoea were significantly lower in the toltrazuril-treated groups. It is concluded that a single metaphylactic treatment with toltrazuril controls coccidiosis of housed calves under various field conditions.
Subject(s)
Cattle Diseases/drug therapy , Coccidiosis/prevention & control , Coccidiostats/therapeutic use , Triazines/therapeutic use , Animals , Cattle , Czech Republic/epidemiology , Eimeria/classification , Germany/epidemiologyABSTRACT
OBJECTIVE: To evaluate the therapeutic effect of the selective muscarinic receptor m1 partial agonist, m2 antagonist, Lu25-109-a compound that directly stimulates muscarinic cholinergic receptors-in patients with probable AD. METHODS: A 6-month, randomized, double-blind, placebo-controlled, parallel group trial comparing three doses of Lu25-109 with placebo was carried out. A total of 496 patients with probable AD with a Mini-Mental State Examination score between 10 and 26 were enrolled at 29 centers and randomized to placebo or Lu25-109 25, 50, or 100 mg tid. The primary efficacy measures were the AD Assessment Scale-Cognitive subscale and the AD Cooperative Study Clinical Global Impression of Change. Secondary efficacy variables included the AD Cooperative Study Inventory of Activities of Daily Living and the Behavioral Symptoms in AD Scale. RESULTS: In both an intent-to-treat and a completer's analysis there were no significant differences for either the two primary or the secondary variables. There was a trend for patients on the highest drug dose to worsen in the completer's analysis. Adverse events included dizziness, nausea, diarrhea, fatigue, increased sweating, and anorexia, all of which increased with increasing drug dose. CONCLUSION: Lu25-109, a selective partial ml agonist and an m2/m3 antagonist, failed to improve cognition in patients with mild to moderate AD.
Subject(s)
Alzheimer Disease/drug therapy , Cognition/drug effects , Muscarinic Agonists/administration & dosage , Pyridines/administration & dosage , Tetrazoles/administration & dosage , Aged , Aged, 80 and over , Alzheimer Disease/genetics , Apolipoproteins E/genetics , Cholinergic Fibers/chemistry , Cholinergic Fibers/drug effects , Double-Blind Method , Female , Genotype , Humans , Male , Middle Aged , Muscarinic Agonists/adverse effects , Pyridines/adverse effects , Receptor, Muscarinic M1 , Receptors, Muscarinic/physiology , Tetrazoles/adverse effects , Treatment FailureABSTRACT
Lu 25-109 is a functionally selective partial M1 agonist with M2/M3 antagonist properties. This double-blind, placebo-controlled, two-part, inpatient bridging study was designed to evaluate the safety and tolerability of multiple oral doses of Lu 25-109 in patients with Alzheimer's Disease(AD), and to determine the maximum tolerated dose (MTD) in this population. In the first part of the study, the fixed-dose MTD was to be determined in five consecutive panels of 6 patients each (4 Lu 25-109/2 placebo). Doses for the five panels were 100, 125, 150, 200, and 225 mg tid for 7 days. Cholinergic adverse events such as increased salivation, dizziness, and gastrointestinal symptoms were observed at all doses studied. The dosing of fixed-dose panels was discontinued after 3 days at 200 mg tid due to unacceptable gastrointestinal adverse events. Thus, 150 mg tid was defined as the fixed-dose MTD. The second part of the study, conducted in a single panel of 8 patients (6 Lu 25-109/2 placebo), was designed to determine if patients could tolerate higher doses of Lu 25-109 when administered on a titration regimen. Patients were to receive doses that were 50%, 75%, 100%, 125%, and 150% of the fixed dose MTD, with dose increases every five days. The first dose, 75 mg tid, was very well-tolerated; however, as in the first phase of the study, patients did not tolerate the 200 mg tid dose. Thus, the titration regimen employed did not improve the overall tolerability of Lu 25-109.
Subject(s)
Alzheimer Disease/drug therapy , Muscarinic Agonists/therapeutic use , Pyridines/therapeutic use , Tetrazoles/therapeutic use , Aged , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Middle Aged , Muscarinic Agonists/administration & dosage , Muscarinic Agonists/adverse effects , Placebos , Pyridines/adverse effects , Pyridines/pharmacology , Tetrazoles/adverse effects , Tetrazoles/pharmacologyABSTRACT
The pharmacokinetics of tiagabine after single-dose (8 mg) and multiple-dose (3 mg, three-times daily for four days) administration of tiagabine HCl were investigated in healthy elderly volunteers (n = 8; Group 1), elderly patients with epilepsy receiving at least one hepatic enzyme-inducing antiepileptic drug (AED) (n = 8; Group 2), and healthy young volunteers (n = 8; Group 3). Participants were matched by gender, age (Groups 1 and 2), alcohol intake, body weight, and whether they smoked tobacco. The pharmacokinetic parameters of tiagabine following single- and multiple-dose administration were similar in both healthy elderly and young volunteers except for a small but significant difference in the area under the concentration-time curve after multiple-doses (103 +/- 29 ng.hr/mL/mg in the elderly versus 72 +/- 20 ng.hr/mL/mg in younger participants). This is not expected to have any clinical relevance because of the large intersubject variability in this parameter. In contrast, and as expected, the pharmacokinetics of tiagabine were altered in the presence of enzyme-inducing antiepileptic drugs: Time to reach maximum plasma concentration, area under the concentration-time curve, and elimination half-lives were significantly lower (e.g. 39 +/- 13 ng.hr/mL/mg for AUC after multiple-dose) compared with corresponding values in the healthy volunteers. These findings suggest that adjusting the dose of tiagabine on the basis of the age of the patient is not necessary, although, irrespective of age, higher doses and/or more frequent administrations will be required in patients taking concomitant enzyme-inducing antiepileptic drugs.
Subject(s)
Anticonvulsants/pharmacokinetics , Epilepsy/metabolism , Nipecotic Acids/pharmacokinetics , Adult , Age Factors , Aged , Anticonvulsants/administration & dosage , Anticonvulsants/adverse effects , Anticonvulsants/chemistry , Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Female , Humans , Male , Middle Aged , Nipecotic Acids/administration & dosage , Nipecotic Acids/adverse effects , Nipecotic Acids/chemistry , Sex Factors , TiagabineABSTRACT
Tiagabine (TGB) HCl, a new antiepileptic compound, is a potent and specific inhibitor of gamma-aminobutyric acid (GABA) uptake. In conjunction with three phase I studies, the pharmacokinetics of TGB were examined in 58 healthy male volunteers. Study I involved single increasing doses (2-24 mg TGB HCl); study II involved doses of 2-10 mg given once daily for 5 days; study III explored one dose daily (6 or 12 mg) for 14 consecutive days. Plasma TGB concentrations were measured by high-performance liquid chromatography (HPLC). Pharmacokinetic parameters were calculated by standard noncompartmental methods. Pharmacokinetic profiles were similar in all three studies and indicated that the processes of absorption and elimination of TGB were linear. The drug was rapidly absorbed, and half-life (t1/2) averaged 5-8 h. The accumulation ratio was fairly low: < 1.4 in most subjects. Secondary peaks in plasma concentration-time profiles suggested enterohepatic recycling. Lack of significant effects on antipyrine clearance indicated that TGB does not induce or inhibit hepatic microsomal enzyme systems.
Subject(s)
Neurotransmitter Uptake Inhibitors/pharmacokinetics , Nipecotic Acids/pharmacokinetics , gamma-Aminobutyric Acid/pharmacokinetics , Administration, Oral , Adult , Anticonvulsants/blood , Anticonvulsants/pharmacokinetics , Chromatography, High Pressure Liquid , Dose-Response Relationship, Drug , Half-Life , Humans , Male , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Nipecotic Acids/blood , Placebos , Tiagabine , gamma-Aminobutyric Acid/bloodABSTRACT
Tiagabine is a new antiepileptic drug which acts by a novel mechanism, inhibiting the reuptake of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) into neurons and glia. A double-blind, placebo-controlled, crossover trial was undertaken, based upon a response-dependent design. Ninety-four patients with complex partial seizures with or without secondary generalised tonic-clonic seizures were recruited into an open screening phase and tiagabine was added to their existing drug therapy in doses titrated to reduce seizure frequency by > or = 25% or to the limit of tolerance. Forty-six responders were subsequently randomised to a double-blind crossover trial in which tiagabine was compared with placebo. Forty-two patients completed the trial. A significant reduction in the frequency of complex partial and secondary generalised tonic clonic seizures was seen. Twenty-six percent had a reduction of > or = 50% in the frequency of their complex partial seizures, and of the 27 patients who also had secondary generalised tonic clonic seizures, 63% experienced a reduction of > or = 50%. No interactions with baseline antiepileptic drugs were detected and no serious adverse reactions occurred. The commonest adverse events were tiredness, dizziness and headache. We conclude that tiagabine has promising antiepileptic effects. Further trials are underway.
Subject(s)
Anticonvulsants/therapeutic use , Epilepsies, Partial/drug therapy , Nipecotic Acids/therapeutic use , Adolescent , Adult , Aged , Double-Blind Method , Humans , Middle Aged , Placebos , Tiagabine , Treatment OutcomeSubject(s)
Home Care Services , Spinal Muscular Atrophies of Childhood/nursing , Family , Home Nursing , Humans , Infant , MaleABSTRACT
Tiagabine (TGB), a specific gamma-aminobutyric acid (GABA)-uptake inhibitor, is a potential new antiepileptic drug with a novel mechanism of action. In animal models of epilepsy as well as in a placebo-controlled trial in patients with complex partial seizures, TGB showed significant anticonvulsant effects. TGB was well tolerated by most patients.
Subject(s)
Anticonvulsants/pharmacology , Nipecotic Acids/pharmacology , Acoustic Stimulation , Animals , Anticonvulsants/pharmacokinetics , Anticonvulsants/therapeutic use , Clinical Trials as Topic , Drug Evaluation, Preclinical , Drug Interactions , Epilepsy, Complex Partial/drug therapy , Humans , Male , Mice , Nipecotic Acids/pharmacokinetics , Nipecotic Acids/therapeutic use , Rats , Rats, Wistar , Seizures/prevention & control , TiagabineABSTRACT
A single-blind, placebo-controlled, cross-over trial investigating possible interactions between paroxetine, a serotonin re-uptake inhibitor, and carbamazepine (CBZ), valproate (VPA) and phenytoin (PHT) was carried out in 20 outpatients with epilepsy. Patients on long-term treatment with CBZ, VPA, or PHT were given a 7-day placebo treatment, followed by paroxetine co-treatment for 16 days. Side effects were infrequent and mild. Paroxetine caused no changes in the plasma concentrations and all values were within the recommended ranges. No changes in protein binding were found. Plasma concentrations of paroxetine at steady state (8-147 ng/ml) were in the normal range for a 30-mg daily dosing regimen. None of the patients experienced epileptic seizures during the study.
Subject(s)
Antidepressive Agents/pharmacology , Carbamazepine/pharmacology , Phenytoin/pharmacology , Piperidines/pharmacology , Valproic Acid/pharmacology , Adult , Drug Interactions , Female , Humans , Male , Middle Aged , Paroxetine , Single-Blind MethodSubject(s)
Anticonvulsants/therapeutic use , Drugs, Investigational/therapeutic use , Epilepsy/drug therapy , Nipecotic Acids/therapeutic use , Animals , Anticonvulsants/adverse effects , Anticonvulsants/pharmacokinetics , Brain/drug effects , Drugs, Investigational/adverse effects , Drugs, Investigational/pharmacokinetics , Electroencephalography/drug effects , Epilepsy/blood , Evoked Potentials/drug effects , Humans , Mice , Nipecotic Acids/adverse effects , Nipecotic Acids/pharmacokinetics , Rats , TiagabineABSTRACT
In a 14-day multiple-dose study the pharmacokinetics of paroxetine was investigated in 12 patients with alcoholic cirrhosis and in 6 subjects without liver disease. The dose of 20-30 mg paroxetine daily was adjusted to the reduction in liver function, as assessed by the galactose elimination capacity. Accordingly, all but two of the cirrhotic patients received 20 mg, while all six control subjects received 30 mg. Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.ml-1 per mg paroxetine and 89 vs 43 h (ng).ml-1 per mg paroxetine]. The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism. All but two patients with cirrhosis experienced nausea during the first two or three days after the first dose, while none of the controls had this symptom. The study showed slower elimination of paroxetine and consequently higher plasma levels in patients with cirrhosis, suggesting that in the latter the dose of paroxetine should be in the lower end of the therapeutic range.
Subject(s)
Liver Cirrhosis, Alcoholic/metabolism , Piperidines/pharmacokinetics , Serotonin Antagonists/pharmacokinetics , Adult , Aged , Cimetidine/metabolism , Disulfiram/metabolism , Drug Interactions , Female , Half-Life , Humans , Liver Function Tests , Male , Middle Aged , Paroxetine , Piperidines/administration & dosage , Piperidines/adverse effects , Serotonin Antagonists/administration & dosage , Serotonin Antagonists/adverse effectsABSTRACT
The pharmacokinetics of abecarnil (isopropyl 6-(benzyloxy)-4-(methoxymethyl)-9H-pyrido [3,4-b] indole-3-carboxylate, ZK 112 119) were studied in the mouse, rat, rabbit, dog, cynomolgus monkey and baboon using 14C-labeled drug and HPLC with fluorescence detection for measurement of unchanged drug. Abecarnil was rapidly and completely absorbed after oral doses of 10 mg/kg. At higher doses, absorption was prolonged and incomplete in the cynomolgus monkey. The bioavailability of abecarnil was 20-30% in all the species investigated. The terminal half-life of the unchanged drug in plasma was relatively similar in all species (0.6-1.7 h). Abecarnil was able to pass the blood-brain barrier achieving concentrations in the brain similar to those in plasma. Tissue distribution of labeled compounds was rapid with highest concentrations in the liver, adrenals, kidneys and pancreas followed by the bone marrow, lungs, heart, fat, spleen, ovaries and thyroid gland. Excretion of radiolabeled compounds proceeded predominantly in the feces of the rat, the rabbit and the cynomolgus monkey.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Carbolines/pharmacokinetics , Animals , Autoradiography , Biological Availability , Blood-Brain Barrier/drug effects , Dogs , Female , Half-Life , Intestinal Absorption , Macaca fascicularis , Male , Mice , Papio , Rabbits , Rats , Species Specificity , Tissue DistributionABSTRACT
A high-performance liquid chromatographic (HPLC) method for the determination of an oxadiazole-substituted 1,4-benzodiazepine [3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo -4H-imidazo[1,5a] [1,4]benzodiazepine] in plasma has been developed and compared with a radioreceptor assay. The results given by the two methods were in good agreement, with detection limits of ca. 1 ng/ml (signal-to-noise ratio = 3). The radioreceptor method is preferred for the monitoring of toxicological and other well controlled studies, while HPLC is preferred where greater specificity is essential. Further, the HPLC assay is applicable over a much wider concentration range.
Subject(s)
Anti-Anxiety Agents/blood , Benzodiazepines/blood , Chromatography, High Pressure Liquid/methods , Radioligand Assay , Animals , Drug Interactions , Haplorhini/blood , Humans , Rats/blood , Spectrophotometry, UltravioletABSTRACT
An assay procedure for measuring plasma, urine, and feces levels of seven beta-carbolines and possible metabolites is described. The drugs are extracted with diethylether or, alternatively, with a commercially available automated extraction device after adding an appropriate internal standard. Separation from matrix constituents is performed by reversed-phase high-performance liquid chromatography (HPLC) followed by fluorescence detection. The carboxylic acid metabolites of the beta-carbolines have to be esterified before HPLC measurement. The detection limits are 0.2 ng/mL for beta-carbolines and 2 ng/mL for their metabolites. Plasma levels and pharmacokinetic parameters of six different beta-carbolines in healthy male volunteers following iv or po treatment are described. Total clearance ranged from 17 to 52 mL/min/kg and the terminal half-life ranged from 1 to 4 h. The absolute bioavailability exhibited a range from less than 1 to 61%.
Subject(s)
Carbolines/analysis , Administration, Oral , Adult , Carbolines/blood , Carbolines/urine , Carboxylic Acids/metabolism , Chromatography, High Pressure Liquid , Feces/analysis , Humans , Injections, Intravenous , Male , Spectrometry, FluorescenceABSTRACT
All types of gastric resections induce an abnormal release of gastrointestinal hormones. The missing duodenal passage seems to be the most important factor for these disturbances. In the present study we have examined the effect of exclusion and restoration of the duodenal passage on the postprandial release of neurotensin in dogs. After feeding a standard canned dog meal, exclusion of the duodenal passage by a Billroth-II-resection caused a significant increase in postprandial neurotensin release compared to the control group (peak levels 52 +/- 5.6 to 29 +/- 6 pg/ml preoperatively, integrated output 2132 +/- 228 to 3604 +/- 213 pg/ml x 150 min. p less than 0.05). Reconstruction of the duodenal passage by the Biebl-Henly-Soupault-procedure tended the elevated neurotensin levels towards normal (peak levels 36 +/- 4.8 pg/ml, integrated output 2448 +/- 236 pg/ml x 150 min., p less than 0.05). From our data we conclude that changes in intestinal transit time are responsible for the pathological increase in neurotensin release after exclusion of the duodenal passage.
Subject(s)
Neurotensin/metabolism , Animals , Dogs , Duodenum/metabolism , Duodenum/surgery , Eating , Intestinal Absorption , Postgastrectomy Syndromes/metabolismABSTRACT
To evaluate the pharmacokinetic properties, efficacy, and tolerability of paroxetine in elderly depressed patients, a clinical study was set up--initially at Aalborg Psychiatric Hospital in Denmark, and subsequently at the University Hospital in Linköping, Sweden. A total of 21 patients with a median age of 72 years were included in the study. After a single dose of 20 or 30 mg of paroxetine followed by two drug-free days, treatment continued with 20 or 30 mg daily for seven weeks. The majority of patients showed a continuous reduction in their HAMD scores, starting in the second week of treatment. Paroxetine was well tolerated at the doses given, and side-effects were mostly mild and transient. Steady-state, pre-dose plasma levels of paroxetine showed considerable variability, and the median steady-state concentration was higher in elderly patients compared with data from a previous study in young volunteers. Elimination half-lives also showed variability between these elderly patients, but tended to be longer after cessation of multiple dosing than after a single dose. They also tended to be longer than in the young volunteers. The results of this study do not advocate reduced doses of paroxetine in the elderly, but further studies are warranted.
Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/drug therapy , Piperidines/therapeutic use , Serotonin Antagonists/therapeutic use , Aged , Aged, 80 and over , Antidepressive Agents/pharmacokinetics , Clinical Trials as Topic , Depressive Disorder/blood , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Paroxetine , Piperidines/pharmacokinetics , Psychiatric Status Rating Scales , Serotonin Antagonists/pharmacokineticsABSTRACT
The possibility of a pharmacokinetic interaction between femoxetine and cimetidine has been evaluated in 8 healthy volunteers. Two volunteers received single doses of femoxetine, and 6 were given multiple doses of femoxetine for 7 days with and without concurrent cimetidine. No influence of cimetidine was observed on the kinetics of single doses of femoxetine, but after multiple doses the plasma concentration of femoxetine was significantly increased. Similarly, the AUC at steady state tended to be increased, but not to a significant extent. Concurrent cimetidine did not cause a reduction in the AUC of the active desmethyl metabolite. It is recommended that femoxetine is given in reduced doses (e.g. 400 mg) when administered with cimetidine.